Search research articles
Contact Us
Filters
Showing results (231-240 of 259) with videos related to
Page
of 26
Sort By:
The Lancet. Oncology
|
April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
Nature
|
March 28, 2014
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun, Liqin Wang, Sidong Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
Takeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, et al.
Cancer Discovery
|
May 21, 2020
EGFR Blockade Reverts Resistance to KRAS<sup>G12C</sup> Inhibition in Colorectal Cancer
Vito Amodio, Rona Yaeger, Pamela Arcella, et al.
Nature Medicine
|
June 2, 2015
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, et al.
Nature Communications
|
August 22, 2025
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Lisa Brunet, David Alexandre, Jiyoung Lee, et al.
JAMA Oncology
|
February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial
Clara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
BMC Cancer
|
April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Francesca Aroldi, Elena Elez, Thierry André, et al.
Journal of the National Cancer Institute
|
January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
Cancer Research
|
June 18, 2016
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Daniele Oddo, Erin M Sennott, Ludovic Barault, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 259) with videos related to
Sort By:
Page
of 26
The Lancet. Oncology
|
April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
Nature
|
March 28, 2014
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun, Liqin Wang, Sidong Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
Takeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, et al.
Cancer Discovery
|
May 21, 2020
EGFR Blockade Reverts Resistance to KRAS<sup>G12C</sup> Inhibition in Colorectal Cancer
Vito Amodio, Rona Yaeger, Pamela Arcella, et al.
Nature Medicine
|
June 2, 2015
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, et al.
Nature Communications
|
August 22, 2025
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Lisa Brunet, David Alexandre, Jiyoung Lee, et al.
JAMA Oncology
|
February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial
Clara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
BMC Cancer
|
April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Francesca Aroldi, Elena Elez, Thierry André, et al.
Journal of the National Cancer Institute
|
January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
Cancer Research
|
June 18, 2016
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Daniele Oddo, Erin M Sennott, Ludovic Barault, et al.
Page
of 26